Last checked at 15 Dec 2023 17:08
European shares end fifth week higher on rate-cut optimism
Barclays sees first ECB rate cut in April
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Glaxosmithkline Share News (GSK)
GSK Share
Price
GSK Share
News1
GSK Share
Chat2
GSK Share
Trades3,449
GSK
Live RNS
GSK Share
Charts
GSK Level 2
Console
GSK Live
Share Price
GSK Broker
Ratings
GSK Directors
Deals
GSK Financial
Diary
GSK
Fundamentals
GSK Short
Positions
GSK
Media
Glaxosmithkline Information
Share Price Information for Glaxosmithkline (GSK)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
1,699.00
Bid:
1,698.50
Ask:
1,699.50
Change:
-6.00 (-0.35%)
Spread:
1.00 (0.059%)
Open:
1,705.00
High:
1,711.00
Low:
1,695.50
Prev. Close:
1,705.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.London midday: Mining rebound lifts markets higher
Fri, 19th Apr 2013 11:57
The FTSE 100 rebound on Friday morning after a five-day losing streak as strong gains in the mining sector lifted London's benchmark higher."Clients who went bargain hunting in the mining space after the aggressive sell-off earlier in the week have been rewarded this morning, as the sector bounces back strongly early on," said Matt Basi, the Head of UK Sales Trading at CMC Markets.Ahead of today's session, the FTSE 100 had lost 2.7% of its value after five consecutive falls as disappointing US earnings and concerns over global growth weighed on sentiment.First-quarter economic gross domestic product figures from China, a plummeting gold price and downwards revisions to global growth forecasts by the International Monetary Fund caused some volatile swings in the mining sector earlier this week. Before today, FTSE 350 mining stocks had fallen by an average 9.14% since last Friday.FTSE 100: Miners provide a liftMining stocks were performing well after a volatile week for the sector. ENRC, Vedanta, EVRAZ and Randgold were all making decent gains by lunchtime.Anglo American was also a high riser after announcing that production at its larger operations of iron ore and copper increased in the first quarter, when compared with last year, despite the company scaling back spending.Meanwhile, telecoms firm Vodafone was also in demand as rumours continue to circulate surrounding a buy-out of its 45% stake in its US wireless joint venture with Verizon. According to reports this morning, a deal could happen this year as fears about tax obstacles ease.GlaxoSmithKline was trading lower ahead of its first-quarter update next week. There were reports this morning that the company is being investigated over claims it paid off firms to delay the launch of cheap versions of its anti-depression drug.FTSE 250: Spectris plummets after weak first quarterSpectris, the electrical engineering firm, plummeted after reporting an 8.0% fall in first-quarter sales, reflecting a deferral of orders and shipment delaysHigh Street bookie William Hill surged early on despite reporting that growth had moderated during the first quarter. The firm did say however that the Grand National after the quarter-end was a "major success", beating its record win achieved on the race in 2009.Online information and events group Euromoney fell after announced that it has acquired a 75% stake in the Australian provider of investment forums, Centre for Investor Education.
More News
15 Dec 2023 16:51
LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools
(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.
Read more15 Dec 2023 16:29
PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg
(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.
Read more12 Dec 2023 10:08
AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal
Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.
Read more12 Dec 2023 08:22
TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine
(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.
Read more12 Dec 2023 07:39
LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI
(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.
Read more12 Dec 2023 07:24
GSK seeks to extend RSV vaccine approval in Japan
(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.
Read more11 Dec 2023 08:28
GSK drug gets EU marketing backing for form of endometrial cancer
(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.
Read more11 Dec 2023 07:41
LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook
(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.
Read more11 Dec 2023 07:23
GSK endometrial cancer treatment gets Europe authorisation
(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.
Read more7 Dec 2023 12:54
THG backer Kelso pushes for demerger to trim "inherent" valuation gap
(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.
Read more5 Dec 2023 10:02
LONDON BROKER RATINGS: Goldman lifts Landsec and British Land
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:
Read more27 Nov 2023 09:00
GSK announces positive results from Blenrep phase 3 blood cancer trial
(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.
Read more27 Nov 2023 08:02
GSK receives 'positive' headline results from phase III trial
(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.
Read more22 Nov 2023 09:48
LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more